Ginger may ease the nausea that appears a day or more after chemotherapy, but the result depends on which study you read. In a blinded Australian trial, people taking standardized ginger capsules reported less delayed nausea and better nausea-related quality of life than people taking placebo capsules. The trial gives a useful reason to discuss ginger with an oncology team. It does not show that ginger works for every chemotherapy regimen or that ginger tea can replace a tested capsule. The Crichton trial (https://pubmed.ncbi.nlm.nih.gov/37699474/) is the main study behind that distinction.
The difference between feeling sick and actually vomiting matters here. A person can have little vomiting yet still struggle to eat, drink, travel, or sleep because of persistent nausea. The Australian researchers measured both symptoms and the disruption they caused. Their strongest results concerned delayed nausea and daily life, while they found no benefit for nausea in the first 24 hours after treatment.
What the Australian researchers tested
The team enrolled 103 adults at two Australian hospitals. All were starting chemotherapy that carried a moderate or high risk of nausea and vomiting. The two groups were split almost evenly between ginger and a placebo made to look like the ginger capsules. Participants, clinicians, and the people assessing outcomes were initially kept unaware of the assignment. That masking helps limit the effect of expectations on symptom reports, although it did not hold perfectly in this trial.
Everyone continued their prescribed anti-nausea care. The question was whether ginger added anything to it. Participants took four standardized capsules each day, starting on the day of chemotherapy and continuing for five days, during each of their first three treatment cycles. The four capsules contained a total of 1.2 grams of ginger root powder and supplied about 84 milligrams per day of compounds called gingerols and shogaols. That smaller number describes measured compounds within the powder, not the total weight of ginger. A supermarket tea, fresh root, or an unstandardized supplement cannot be assumed to deliver the same exposure. The Crichton trial (https://pubmed.ncbi.nlm.nih.gov/37699474/) reports the formulation and schedule.
The main outcome was nausea-related quality of life, meaning how much nausea interfered with ordinary activities. The investigators also tracked vomiting, nausea at different times, fatigue, nutrition, mood, and adverse events. Their analysis included all 103 randomized participants, using a statistical method to fill gaps in missing follow-up data. Only 70 completed all three cycles. That loss leaves more uncertainty about later-cycle results than the phrase all participants analyzed might suggest. Starting with people who had not previously received chemotherapy helped the team examine symptoms across the early cycles, when both the treatment and the experience were new.
The ginger group improved more on the main nausea-related quality-of-life measure. The reported probability value was 0.003, at the study's stated cutoff after adjustment for multiple comparisons. Delayed nausea severity and fatigue also favored ginger. The researchers called the differences in nausea-related and overall nausea-and-vomiting quality of life clinically relevant. A probability value indicates how compatible the data are with a no-difference model; it does not tell an individual patient how much relief to expect. The Crichton trial (https://pubmed.ncbi.nlm.nih.gov/37699474/) provides the outcomes and analysis plan.
The timing gives the result practical meaning. Delayed symptoms occur after the first day, sometimes when someone has already returned home. In cycle two, delayed nausea was reported by 53% of the ginger group and 75% of the placebo group. In cycle three, the figures were 49% and 79%. The cycle-two difference did not meet the paper's stricter cutoff after correction for multiple tests; the cycle-three difference did. Delayed vomiting was less common in the ginger group in those cycles too, though the average number of vomiting episodes was low and its difference was not judged clinically meaningful. These are group findings from this particular study, not a prediction of what will happen in another cancer clinic.
The researchers saw no effect on anticipatory nausea, the queasy feeling that can begin before treatment, or on acute nausea and vomiting in the first 24 hours. They also found no effect on broad health-related quality of life, anxiety, or depression. Reporting those null results is necessary because a headline about ginger and chemotherapy can otherwise sound much wider than the data allow. The study enrolled fewer people than planned, and use of the prescribed anti-nausea medicines could not be reliably reconstructed. More ginger recipients than placebo recipients guessed their assignment correctly, often because of ginger-tasting burps. Self-reported symptoms could be influenced by that clue. The open full paper (https://publications.aston.ac.uk/id/eprint/48721/1/Effect_of_a_Standardized_Ginger_Root_Powder_Regimen_on_Chemotherapy-Induced_Nausea_and_Vomiting.pdf) describes these limits.
Why other ginger trials do not line up neatly
A larger North American trial reached a different result for a different time window. Researchers randomized 744 people who had already experienced nausea during chemotherapy; 576 had data for the final analysis. They compared placebo with three daily ginger doses, 0.5, 1.0, and 1.5 grams. Participants began capsules three days before chemotherapy and continued for six days. All received an anti-nausea medicine on treatment day. In this study, ginger reduced nausea severity on that first day, with the clearest reductions at 0.5 and 1.0 grams. The Ryan trial (https://pubmed.ncbi.nlm.nih.gov/21818642/) measured acute symptoms as its main question, whereas the Australian trial found its clearest gain after the first day.
The two studies do not prove that an earlier start treats immediate nausea and a same-day start treats delayed nausea. Their patients, products, doses, anti-nausea regimens, and outcome measures differed. Only a trial that directly compared schedules under otherwise similar conditions could test that idea. The older study also lost a substantial share of randomized participants before analysis, which makes its estimate less secure than its headline number suggests.
A European multicenter study provides a sharper caution. It randomized 251 people receiving high-dose cisplatin to a standardized ginger extract or placebo in addition to their regular anti-nausea medicines. Ginger began the day after cisplatin, and the main question was delayed nausea. The study did not find a meaningful difference in delayed nausea, nausea between cycles, or anticipatory nausea. Only 154 participants completed study treatment, another reason to read the result with care. The Bossi trial (https://pubmed.ncbi.nlm.nih.gov/28666335/) tested a different extract and a specific, highly nausea-provoking regimen. Its negative result cannot erase the Australian finding, and the Australian finding cannot erase it.
A smaller placebo-controlled study in 48 women receiving cisplatin with radiotherapy for cervical cancer also found no convincing improvement in nausea or vomiting over six weeks. It assigned 16 women each to two ginger-dose groups and placebo. That small sample could miss a modest effect, but it still warns against describing ginger as dependable relief across cancer treatments. The dos Santos trial (https://pubmed.ncbi.nlm.nih.gov/38140826/) is especially relevant when someone asks whether ginger will work with a cisplatin and radiation schedule.
Another randomized study of 172 hospitalized patients compared usual care with ginger, wrist acupressure at the P6 point, or both. Its ginger-only group improved on delayed nausea and a nausea-related daily-function score, without clear benefit for acute nausea or delayed vomiting. Because it compared several active approaches and did not supply the same kind of blinded capsule comparison as the Australian trial, it adds context rather than settling the question. The Xiao trial (https://pubmed.ncbi.nlm.nih.gov/38461442/) also prevents an easy assumption that a combined ginger-and-acupressure result belongs to ginger alone.
The pattern is mixed, which is also how the US National Cancer Institute describes the ginger evidence in its clinical summary (https://www.cancer.gov/about-cancer/treatment/side-effects/nausea/nausea-hp-pdq). Different outcomes explain some apparent disagreement. A study asking about first-day nausea can miss an effect confined to later days. Different chemotherapy drugs, doses, and products may matter too. Those are plausible explanations, not established rules for choosing a ginger regimen.
What a patient can take from the evidence
The most defensible use of this research is a conversation about a possible add-on for delayed nausea. Someone might ask their cancer team whether a ginger supplement is appropriate with their exact chemotherapy and other medicines, and whether there is a product with clearly stated ingredients. The Australian trial tested a standardized capsule, not a recipe for home dosing. Copying its 84 milligrams of active compounds from a label is difficult because many labels state only total root or extract weight.
Someone who likes ginger in food or a warm drink can still enjoy it if their care team says it is suitable. Food use is a different question from the clinical-trial result. Ginger tea may feel soothing, but this trial cannot tell us that it prevents chemotherapy nausea. The National Center for Complementary and Integrative Health (https://www.nccih.nih.gov/health/ginger/) says evidence for ginger as an addition to cancer nausea care remains uncertain and notes that most research used supplements rather than foods.
The older Healthy Mango article on ginger and ovarian cancer discusses a separate research question. Relief of a treatment side effect is not evidence that ginger treats a tumor. Keeping those questions apart protects both the useful symptom research and the reader's decisions about cancer care.
Safety and the point at which to call for help
Ginger supplements can cause heartburn, abdominal discomfort, diarrhea, or irritation in the mouth and throat. In the Australian trial, reflux or heartburn was reported by 18% of ginger recipients and 2% of placebo recipients; one person in the ginger group withdrew because of it. The full Crichton paper (https://publications.aston.ac.uk/id/eprint/48721/1/Effect_of_a_Standardized_Ginger_Root_Powder_Regimen_on_Chemotherapy-Induced_Nausea_and_Vomiting.pdf) reported no serious adverse event thought related to the capsules. The trial excluded people with certain conditions or medicines, including clotting disorders, liver disease, anticoagulants, and nonsteroidal anti-inflammatory drugs. Its safety findings cannot simply be transferred to them.
Herbs can also interact with medicines. The NCCIH ginger safety page (https://www.nccih.nih.gov/health/ginger/) advises people who take medicines to check with a health professional before using ginger products. That check matters during chemotherapy, when supportive medicines, other conditions, and planned procedures may affect what is sensible for one person. A trial of 103 participants cannot rule out uncommon harms or interactions in a broader group.
Persistent vomiting deserves prompt attention rather than another experiment with tea or capsules. It can cause dehydration, changes in body salts, and weight loss. The National Cancer Institute's patient guidance (https://www.cancer.gov/about-cancer/treatment/side-effects/nausea-vomiting) explains the timing of nausea and why it should be discussed with the care team. If someone cannot keep fluids down, is getting weaker, or has symptoms despite the prescribed plan, the team can assess the cause and adjust that plan.
Ginger has a plausible place in a discussion about delayed chemotherapy nausea because a well-controlled trial found a meaningful benefit in that setting. The conflicting trials keep the conclusion narrow. The person in front of the clinician has a particular regimen, medication list, and pattern of symptoms. Those details matter more than a general claim that ginger works or fails.
